DOACs may benefit patients at intermediate risk of AF
MDSpire News
October 2, 2026
You now have access to the trusted editorial news and specialty content you've known from the Conexiant news site—all within the MDSpire experience.
Learn more

Direct oral anticoagulants (DOACs) may reduce composite clinical events in patients with atrial fibrillation at intermediate stroke risk.
The study enrolled 1,803 patients with a CHA₂DS₂-VASc score of 1 in men or 2 in women, randomly assigning them to DOACs or no anticoagulation.
The primary outcome occurred in 4 patients receiving DOACs compared to 13 patients receiving no anticoagulation over 24 months.
Serious adverse events were reported in 80 patients receiving DOACs and 84 patients receiving no anticoagulation.
The study's limitations include a lower-than-expected number of outcome events and potential biases due to its open-label design.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Affiliations:
Specialties:
Areas of Expertise: